Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 12,000 shares at $20.11 ($241K) on 2026-03-25, disclosed to the SEC on 2026-03-27.
Scheduled sale ($241k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |